AR095570A1 - Derivados de urea - Google Patents
Derivados de ureaInfo
- Publication number
- AR095570A1 AR095570A1 ARP140101193A ARP140101193A AR095570A1 AR 095570 A1 AR095570 A1 AR 095570A1 AR P140101193 A ARP140101193 A AR P140101193A AR P140101193 A ARP140101193 A AR P140101193A AR 095570 A1 AR095570 A1 AR 095570A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- cycloalkyl
- alkyl
- phenyl
- pyridinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1854—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety
- C07C273/1863—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety from urea
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5302—Apparatus specially adapted for immunological test procedures
- G01N33/5304—Reaction vessels, e.g. agglutination plates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Compuestos de fórmula (1), en la que: R¹ y R² conjuntamente con el carbono al que se encuentran unidos forman un cicloalquilo; R³ es H, alquilo o cicloalquilo; R⁴ es H, alquilo o cicloalquilo; W es un enlace, -O-, -S-, -NR⁵-, -C(O)-, -S(O)₂-, -C(O)-NR⁵- ó -CR⁶R⁷-; R⁵ es H, alquilo o cicloalquilo; R⁶ y R⁷ se seleccionan independientemente de entre H, alquilo o cicloalquilo; A es fenilo sustituido, tiofenilo sustituido, benzotiofenilo sustituido, tienopiridinilosustituido, en los que el fenilo sustituido, tiofenilo sustituido, benzotiofenilo sustituido y tienopiridinilo sustituido se sustituyen con R⁸, R⁹ y R¹⁰; B es cicloalquilo sustituido, cicloalquenilo sustituido, piridinilo sustituido, fenilo sustituido, tiofenilo sustituido, benzotiofenilo sustituido, tienopiridinilo sustituido, en los que el cicloalquilo sustituido, cicloalquenilo sustituido, piridinilo sustituido, fenilo sustituido, tiofenilo sustituido, benzotiofenilo sustituido y tienopiridinilo sustituido se sustituyen con R¹¹, R¹² y R¹³; R⁸, R⁹, R¹⁰ se selecciona independientemente de entre H, alquilo, alquenilo, alquinilo, hidroxialquilo, haloalquilo, hidroxihaloalquilo, cicloalquilo, cicloalcenil, cicloalquilalquilo, cicloalquenilalquilo, cicloalquilalcoxi, cicloalcoxi, cicloalcoxialquilo, cicloalquilalcoxialquilo, alcoxi, alcoxialquilo, haloalcoxi, haloalcoxialquilo, alcoxialcoxi, alcoxialcoxialquilo, fenilo, fenilo sustituido, piridinilo, piridinilo sustituido, halógeno, hidroxi, ciano, aminosulfonilo sustituido, aminocarbonilo sustituido, amino sustituido y aminoalquilo sustituido, en los que aminosulfonilo sustituido, aminocarbonilo sustituido, amino sustituido y aminoalquilo sustituido se sustituyen en el átomo de nitrógeno con uno a dos sustituyentes seleccionados independientemente de entre hidrógeno, alquilo, cicloalquilo, cicloalquilalquilo, hidroxialquilo, alcoxialquilo, alquilcarbonilo y cicloalquilocarbonilo, y en los que el fenilo sustituido y el piridinilo sustituido se sustituyen con uno a tres sustituyentes seleccionados de entre alquilo, hidroxialquilo, haloalquilo, cicloalquilo, alcoxi, haloalcoxi, halógeno, hidroxi y ciano; R¹¹, R¹², R¹³ se seleccionan independientemente de entre H, alquilo, alquenilo, alquinilo, hidroxialquilo, haloalquilo, hidroxihaloalquilo, cicloalquilo, cicloalquenilo, cicloalquilalquilo, cicloalquenilalquilo, cicloalquilalcoxi, cicloalcoxi, cicloalcoxialquilo, cicloalquilalcoxialquilo, alcoxi, alcoxialquilo, haloalcoxi, haloalcoxialquilo, alcoxialcoxi, alcoxialcoxialquilo, fenilo, fenilo sustituido, piridinilo, piridinilo sustituido, halógeno, hidroxi, ciano, aminosulfonilo sustituido, aminocarbonilo sustituido, amino sustituido y aminoalquilo sustituido, en los que aminosulfonilo sustituido, aminocarbonilo sustituido, amino sustituido y aminoalquilo sustituido se sustituyen en el átomo de nitrógeno con uno a dos sustituyentes seleccionados independientemente de entre hidrógeno, alquilo, cicloalquilo, cicloalquilalquilo, hidroxialquilo, alcoxialquilo, alquilcarbonilo y cicloalquilocarbonilo, y en los que el fenilo sustituido y el piridinilo sustituido se sustituyen con uno a tres sustituyentes seleccionados de entre alquilo, hidroxialquilo, haloalquilo, cicloalquilo, alcoxi, haloalcoxi, halógeno, hidroxi y ciano; o sales farmacéuticamente aceptable. Reivindicación 18: Procedimiento para preparar un compuesto según cualquiera de las reivindicaciones 1 a 17, que comprende la reacción de un compuesto de fórmula (2) en presencia de un compuesto de fórmula (3) en el que R¹, R², R³, A, B y W ser tal como se define en la reivindicación 1 y en el que R⁴ es H y Rᵃ es H, NO₂ o F.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13160088 | 2013-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095570A1 true AR095570A1 (es) | 2015-10-28 |
Family
ID=47900931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101193A AR095570A1 (es) | 2013-03-20 | 2014-03-17 | Derivados de urea |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9278918B2 (es) |
| EP (1) | EP2991967A1 (es) |
| JP (1) | JP6235048B2 (es) |
| KR (1) | KR101804650B1 (es) |
| CN (1) | CN105308020B (es) |
| AR (1) | AR095570A1 (es) |
| BR (1) | BR112015024109A2 (es) |
| CA (1) | CA2898534C (es) |
| HK (1) | HK1214238A1 (es) |
| MX (1) | MX2015013365A (es) |
| RU (1) | RU2642454C2 (es) |
| TW (1) | TWI629258B (es) |
| WO (1) | WO2014146995A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE057041T2 (hu) | 2015-07-06 | 2022-04-28 | Alkermes Inc | Hiszton deacetiláz hetero-halogén gátlói |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| US10968169B2 (en) | 2016-10-06 | 2021-04-06 | Daiichi Sankyo Company, Limited | Urea derivative |
| HRP20220223T1 (hr) | 2017-01-11 | 2022-04-29 | Alkermes, Inc. | Biciklički inhibitori histon deacetilaze |
| US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
| CN113401281B (zh) * | 2021-08-17 | 2021-11-02 | 南通御美津精密工业有限公司 | 一种船体锚穴外板开口用的关闭装置 |
| CN118103357A (zh) * | 2021-09-15 | 2024-05-28 | 塞洛拉姆股份有限公司 | Fabp4/5抑制剂、使用方法和制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3382406D1 (de) * | 1982-04-08 | 1991-10-17 | Shell Int Research | Neue hydantoine, ihre herstellung und verwendung. |
| CN1290165A (zh) * | 1997-11-10 | 2001-04-04 | 布里斯托尔-迈尔斯斯奎布公司 | 苯并噻唑蛋白酪氨酸激酶抑制剂 |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| AU2003279996B2 (en) * | 2002-10-21 | 2009-07-09 | Janssen Pharmaceutica, N.V. | Substituted tetralins and indanes and their use |
| WO2005044810A1 (en) | 2003-10-30 | 2005-05-19 | Janssen Pharmaceutica, N.V. | Glyt2 modulators |
| FR2869903B1 (fr) * | 2004-05-06 | 2006-06-23 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppary, leur procede de preparation et leur utilisation dans les compositions cosmetiques ou pharmaceutiques |
| JP4047365B2 (ja) * | 2006-01-11 | 2008-02-13 | 生化学工業株式会社 | シクロアルカンカルボキサミド誘導体及びその製造方法 |
| EP2040690B1 (en) * | 2006-06-28 | 2014-08-06 | Sanofi | Inhibitors of cxcr2 |
| WO2008092878A1 (en) * | 2007-02-01 | 2008-08-07 | Glaxo Group Limited | Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders |
| WO2009034062A1 (en) * | 2007-09-11 | 2009-03-19 | Glaxo Group Limited | Compounds which inhibit the glycine transporter and uses thereof in medicine |
| US8815875B2 (en) * | 2008-11-12 | 2014-08-26 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (FABP) |
-
2014
- 2014-03-17 EP EP14710294.1A patent/EP2991967A1/en not_active Withdrawn
- 2014-03-17 WO PCT/EP2014/055224 patent/WO2014146995A1/en active Application Filing
- 2014-03-17 KR KR1020157025421A patent/KR101804650B1/ko active IP Right Grant
- 2014-03-17 MX MX2015013365A patent/MX2015013365A/es active IP Right Grant
- 2014-03-17 TW TW103109994A patent/TWI629258B/zh not_active IP Right Cessation
- 2014-03-17 CN CN201480016538.XA patent/CN105308020B/zh not_active Expired - Fee Related
- 2014-03-17 RU RU2015140599A patent/RU2642454C2/ru active
- 2014-03-17 CA CA2898534A patent/CA2898534C/en active Active
- 2014-03-17 BR BR112015024109A patent/BR112015024109A2/pt not_active Application Discontinuation
- 2014-03-17 AR ARP140101193A patent/AR095570A1/es unknown
- 2014-03-17 JP JP2015560724A patent/JP6235048B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-17 US US14/857,007 patent/US9278918B2/en not_active Expired - Fee Related
-
2016
- 2016-02-23 HK HK16102014.0A patent/HK1214238A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2991967A1 (en) | 2016-03-09 |
| MX2015013365A (es) | 2016-01-08 |
| WO2014146995A1 (en) | 2014-09-25 |
| CA2898534C (en) | 2017-09-19 |
| TW201514138A (zh) | 2015-04-16 |
| JP2016514106A (ja) | 2016-05-19 |
| RU2015140599A (ru) | 2017-04-26 |
| BR112015024109A2 (pt) | 2017-07-18 |
| JP6235048B2 (ja) | 2017-11-22 |
| CN105308020B (zh) | 2018-01-26 |
| US20160002152A1 (en) | 2016-01-07 |
| KR101804650B1 (ko) | 2018-01-10 |
| US9278918B2 (en) | 2016-03-08 |
| RU2642454C2 (ru) | 2018-01-25 |
| HK1214238A1 (zh) | 2016-07-22 |
| KR20150119357A (ko) | 2015-10-23 |
| CN105308020A (zh) | 2016-02-03 |
| CA2898534A1 (en) | 2014-09-25 |
| TWI629258B (zh) | 2018-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095570A1 (es) | Derivados de urea | |
| AR126406A2 (es) | Compuestos de tetrazolinona y su uso | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR098517A1 (es) | Compuestos derivados de octahidro-ciclobuta[1,2-c;3,4-c]dipirrol-2-ilo | |
| ES2618703T3 (es) | Nuevos compuestos diazaspirocicloalcano y azaspirocicloalcano | |
| AR099823A1 (es) | Compuestos bicíclicos de 7 eslabones | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR088625A1 (es) | Derivados de aril-quinolina | |
| AR092645A1 (es) | Derivados biciclicos inhibidores de autotaxina (atx) | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
| AR103297A1 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina | |
| AR092838A1 (es) | COMPUESTOS TIPO PIRROLO-PIRROLIDINONA COMO INHIBIDORES DE LA INTERACCION ENTRE p53 Y MDM2 Y/O MDM4 | |
| AR096450A1 (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR087901A1 (es) | Derivados dihidroquinolina-2-ona como inhibidores de la aldosterona sintasa y procedimiento para su obtencion | |
| ES2659222T3 (es) | 7-azabicíclicos sustituidos y su uso para moduladores de receptores de orexina | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR095422A1 (es) | Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR090678A1 (es) | Derivados de fenil-tetrahidroisoquinolina como inhibidores de la aldosterona-sintasa y un metodo para su sintesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |